Lazard Asset Management LLC Apellis Pharmaceuticals, Inc. Transaction History

Lazard Asset Management LLC

$68.3 Billion
Q3 2024

A detailed history of Lazard Asset Management LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Lazard Asset Management LLC holds 3,202 shares of APLS stock, worth $84,116. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,202

Previous 6,195 48.31%

Holding current value

$84,116

Previous $237,000 61.18%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$28.84 - $41.15 $86,318 - $123,161	-2,993 Reduced 48.31%	3,202 $92,000
Q2 2024 Aug 14, 2024	BUY	$38.07 - $59.71 $128,943 - $202,237	3,387 Added 120.62%	6,195 $237,000
Q1 2024 May 14, 2024	SELL	$55.39 - $72.47 $4.41 Million - $5.78 Million	-79,703 Reduced 96.6%	2,808 $165,000
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $1.24 Million - $2.16 Million	-33,378 Reduced 28.8%	82,511 $4.94 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $2.48 Million - $9.35 Million	104,805 Added 945.55%	115,889 $4.41 Million
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $1.86 Million - $2.26 Million	-24,220 Reduced 68.6%	11,084 $1.01 Million
Q1 2023 May 15, 2023	SELL	$46.59 - $66.96 $2.31 Million - $3.32 Million	-49,516 Reduced 58.38%	35,304 $2.33 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $1.67 Million - $2.36 Million	38,724 Added 84.01%	84,820 $4.39 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $1.52 Million - $2.37 Million	34,053 Added 282.76%	46,096 $3.15 Million
Q2 2022 Aug 09, 2022	BUY	$35.07 - $59.21 $328,255 - $554,205	9,360 Added 348.86%	12,043 $544,000
Q1 2022 May 13, 2022	BUY	$35.46 - $54.12 $95,139 - $145,203	2,683 New	2,683 $136,000
Q4 2021 Feb 09, 2022	SELL	$30.74 - $49.16 $37,994 - $60,761	-1,236 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $38,810 - $86,322	1,236 New	1,236 $40,000
Q2 2021 Aug 12, 2021	SELL	$40.9 - $64.9 $54,151 - $85,927	-1,324 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$40.8 - $57.39 $484,091 - $680,932	-11,865 Reduced 89.96%	1,324 $56,000
Q4 2020 Feb 11, 2021	BUY	$30.79 - $57.2 $406,089 - $754,410	13,189 New	13,189 $754,000
Q4 2019 Feb 13, 2020	SELL	$22.1 - $30.8 $1.16 Million - $1.62 Million	-52,655 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$24.09 - $32.18 $1.27 Million - $1.69 Million	52,655 New	52,655 $1.27 Million

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.89B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.

Account

Lazard Asset Management LLC Apellis Pharmaceuticals, Inc. Transaction History